A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
Open Access
- 31 December 2014
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (7) , 5435-5448
Abstract
Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches.Keywords
This publication has 42 references indexed in Scilit:
- Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifenAnnals of Oncology, 2012
- Overexpression of Sigma1 Receptor and Its Positive Associations With Pathologic TNM Classification in Esophageal Squamous Cell CarcinomaJournal of Histochemistry & Cytochemistry, 2012
- A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma PrognosisClinical Cancer Research, 2011
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene SignatureClinical Cancer Research, 2010
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Characterisation and protein expression profiling of annexins in colorectal cancerBritish Journal of Cancer, 2007
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002